Back

Reliability, validity, and sensitivity of Japanese version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument: application to efficacy assessment of intravenous immunoglobulin administration.

Matsuda, K. M.; Sugimoto, E.; Ako, Y.; Kitamura, M.; Miyahara, M.; Kotani, H.; Norimatsu, Y.; Hisamoto, T.; Kuzumi, A.; Fukasawa, T.; Sato, S.; Yoshizaki, A.

2023-09-20 rheumatology
10.1101/2023.09.19.23295773 medRxiv
Show abstract

ObjectiveThis study aimed to develop and assess the reliability, validity, and sensitivity of Japanese version of the University of California Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (GIT) Instrument 2.0 (the GIT score), as an evaluation tool for GIT symptoms in systemic sclerosis (SSc). MethodsJapanese version of the GIT score was constructed using the forward-backward method. The reliability and validity of this instrument were evaluated in a cohort of 38 SSc patients. Correlation analysis was conducted to assess the relationship between the GIT score and existing patient-reported outcome measures. Additionally, the sensitivity of the GIT score was examined by comparing GIT scores before and after intravenous immunoglobulin (IVIG) administration in 10 SSc-myositis overlap patients, as IVIG has recently demonstrated effectiveness in alleviating GIT symptoms of SSc. ResultsJapanese version of the GIT score exhibited internal consistency and a significant association with the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease. Furthermore, the total GIT score, as well as the reflux and distention/bloating subscales, displayed moderate correlations with the EQ-5D pain/discomfort subscale, Short Form-36 body pain subscale, and its physical component summary. Notably, following IVIG treatment, there was a statistically significant reduction in the total GIT score and most of the subscales. ConclusionWe firstly validated Japanese version of the GIT score in Japanese SSc patients in real-world clinical settings. This instrument holds promise for application in future clinical trials involving this patient population. Key messagesO_LIWhat is already known about this subject? Khanna et al. developed the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract (GIT) Instrument (the GIT score) to assess patient-reported GIT symptoms in individuals with systemic sclerosis (SSc). C_LIO_LIWhat does this study add? We have developed and established the reliability, validity, and sensitivity of the Japanese version of the GIT score in cohorts of Japanese individuals with SSc. C_LIO_LIHow might this impact on clinical practice? This tool can effectively evaluate GIT manifestations in Japanese SSc patients in routine clinical settings, and potentially in clinical trial contexts. C_LI

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.